TABLE III. Published placebo-controlled studies of drugs for motor hyperactivity and inattention. PLA, placebo; each study included subjects with autism; RUPP Autism Network, 2005 and Arnold et al, 2006 included subjects with autism and other pervasive developmental disorders; all ages are in years.

Study	Drug	Subjects	Design	Results
Quintana et al, 1995114	Methyiphenidate	N = 10	2 weeks	Methylphenidate > PLA
		Age = 7 - 11	Crossover
Handen et al, 2000115	Methylphenidate	N = 13	1 week	Methylphenidate > PLA
		Age = 5 - 11	Crossover	8/13 (62%) responded
RUPP Autism Network, 2005116	Methylphenidate	N = 72	1 week	Methylphenidate > PLA
		Age = 5 - 14	Crossover
Arnold et al, 2006127	Atomoxetine	N = 16	6 weeks	Atomoxetine > PLA
		Age = 5 - 15	Crossover
Jaselskis et al, 1992130	Clonidine	N = 8	6 weeks	Clonidine > PLA by teacher and parent,
		Age = 5 - 13	Crossover	but not clinician
				6/8 (75%) responders at 1-year follow-up
Fankhauser et al, 1992131	Clonidine (transdermal)	N = 9	4 weeks	Clonidine > PLA
		Age = 5 - 33	Crossover	6/9 (67%) responders